Document is current

Any future updates will be listed below

Correction: Investigation of the Efficacy and Safety of Xeligekimab (GR1501) in Patients with Moderate-to-Severe Plaque Psoriasis: A Multicenter, Randomized, Double-Blind Phase II Clinical trial

Crossref DOI link: https://doi.org/10.1007/s13555-025-01480-5

Published Online: 2025-07-24

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark